Immunologic Factors

• 

  Subject Areas on Research

  • 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. 
  • A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. 
  • A case of atypical Bartonella henselae infection in a patient with methimazole-induced agranulocytosis. 
  • A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. 
  • A review of cancer immunotherapy toxicity. 
  • A review of chemotherapy trials for malignant mesothelioma. 
  • A systematic review of morphea treatments and therapeutic algorithm. 
  • A whole animal chemical screen approach to identify modifiers of intestinal neutrophilic inflammation. 
  • ADA2 deficiency (DADA2) associated with Evans syndrome and a severe ADA2 genotype. 
  • ALSUntangled No. 16: cannabis. 
  • Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection. 
  • Acute graft-versus-host disease: are we close to bringing the bench to the bedside? 
  • Anti-DNA antibodies--quintessential biomarkers of SLE. 
  • Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease. 
  • Anti-Myelin Oligodendrocyte Glycoprotein Optic Neuritis or Neuroretinitis? 
  • Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. 
  • Antibiotics and Immunotherapy: Too Much of Anything is Bad! 
  • Antivenom Treatment Is Associated with Fewer Patients using Opioids after Copperhead Envenomation. 
  • Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. 
  • Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease. 
  • Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors. 
  • Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. 
  • Autoimmune hepatitis in a child with chronic hepatitis B virus infection. 
  • B cell depletion and pregnancy: Review and applications for MS treatment. 
  • B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. 
  • Biologics in organ transplantation. 
  • Biologics in relapsing polychondritis: a literature review. 
  • Biology and therapy with biologic agents in gynecologic cancer. 
  • Biomimetic nanoparticles for transplantation tolerance. 
  • Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. 
  • CD19: a promising B cell target for rheumatoid arthritis. 
  • CD83: a regulatory molecule of the immune system with great potential for therapeutic application. 
  • Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. 
  • Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. 
  • Characterization of implantable biosensor membrane biofouling. 
  • Cognitive functioning in cancer patients: effect of previous treatment. 
  • Colony-stimulating factors: clinical applications. 
  • Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. 
  • Complement and CD4+ T cells drive context-specific corneal sensory neuropathy. 
  • Comèl-Netherton syndrome defined as primary immunodeficiency. 
  • Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. 
  • Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. 
  • Controlled Lengthwise Assembly of Helical Peptide Nanofibers to Modulate CD8⁺ T-Cell Responses. 
  • Controversies in the Management of Isolated Congenital Atrioventricular Block. 
  • Coronary artery thickening with mucosal lesions in Henoch-Schönlein purpura. 
  • Cost-effectiveness considerations in the treatment of essential thrombocythemia. 
  • Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. 
  • Cytomegalovirus as an immunomodulator across the lifespan. 
  • Diagnosis and management of pemphigus: Recommendations of an international panel of experts. 
  • Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. 
  • Differential effects of donor-specific alloantibody. 
  • Diffuse glomerulonephritis induced in rabbits by small intravenous injections of horse serum. 
  • Does IVIg administration yield improved immune function in very premature neonates? 
  • Early predictors of rapidly evolving multiple sclerosis: A case report. 
  • Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. 
  • Effect of antipyretic analgesics on immune responses to vaccination. 
  • Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. 
  • Effect of modulating macrophage phenotype on peripheral nerve repair 
  • Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of immune checkpoint inhibitors on B cells: relationship to immune-related adverse events. 
  • Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. 
  • Efficacy of remission-induction regimens for ANCA-associated vasculitis. 
  • EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils. 
  • Escherichia coli, but not Staphylococcus aureus triggers an early increased expression of factors contributing to the innate immune defense in the udder of the cow. 
  • Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. 
  • Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. 
  • Fibroblastic rheumatism: a report of 4 cases with potential therapeutic implications. 
  • Genetic immunization with LYVE-1 cDNA yields function-blocking antibodies against native protein. 
  • Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs. 
  • Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. 
  • HIV infection-induced transcriptional program in renal tubular epithelial cells activates a CXCR2-driven CD4+ T-cell chemotactic response. 
  • HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). 
  • Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy. 
  • Host-Directed Therapies for Tuberculosis. 
  • Human IgM Inhibits the Formation of Titan-Like Cells in Cryptococcus neoformans. 
  • ICON: the early diagnosis of congenital immunodeficiencies. 
  • IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR. 
  • Immune checkpoint modulation enhances HIV-1 antibody induction. 
  • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. 
  • Immunology of inflammatory bowel disease: summary of the proceedings of the Subcommittee on Immunosuppressive Use in IBD. 
  • Immunomodulator effect of picroliv and its potential in treatment against resistant Plasmodium yoelii (MDR) infection in mice. 
  • Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. 
  • Immunomodulatory Effects of Fentanyl or Dexmedetomidine Hydrochloride Infusion After Allogeneic Heart Transplantation in Mice. 
  • Immunomodulatory lipid mediator profiling of cerebrospinal fluid following surgery in older adults. 
  • Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer. 
  • Immunotherapy and monoclonal antibody therapies. 
  • Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome. 
  • Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. 
  • Immunotherapy in selected patients with Down syndrome disintegrative disorder. 
  • Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 
  • Individual and combined effects of shear stress magnitude and spatial gradient on endothelial cell gene expression 
  • Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis. 
  • Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. 
  • Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. 
  • Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature. 
  • Investigational therapies for non-muscle invasive bladder cancer. 
  • Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus. 
  • Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. 
  • MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • Management of immune dysfunction after adult cardiac surgery. 
  • Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. 
  • Mast cell activators as novel immune regulators. 
  • Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. 
  • Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. 
  • Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Myelodysplastic syndromes. 
  • Myelodysplastic syndromes: clinical practice guidelines in oncology. 
  • NMR studies of an immunomodulatory benzodiazepine binding to its molecular target on the mitochondrial F(1)F(0)-ATPase. 
  • Neoadjuvant use of ipilimumab in locally advanced melanoma. 
  • New agents and regimens for diffuse large B cell lymphoma. 
  • New insights into Chlamydia intracellular survival mechanisms. 
  • Non-erythroid effects of erythropoietin. 
  • Novel chemotherapies in development for management of castration-resistant prostate cancer. 
  • Novel immunotherapeutic strategies in development for renal cell carcinoma. 
  • Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. 
  • Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. 
  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. 
  • Pathogen Evasion of Chemokine Response Through Suppression of CXCL10. 
  • Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. 
  • Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review. 
  • Point-of-care washing of allogeneic red blood cells for the prevention of transfusion-related respiratory complications (WAR-PRC): a protocol for a multicenter randomised clinical trial in patients undergoing cardiac surgery. 
  • Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. 
  • Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. 
  • Prescription Treatment Options. 
  • Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. 
  • Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. 
  • Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. 
  • Prospects of immune checkpoint modulators in the treatment of glioblastoma. 
  • Prostaglandin-mediated effects in early canine corpus luteum: In vivo effects on vascular and immune factors. 
  • Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. 
  • Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. 
  • Regression of atherosclerosis with therapeutic antibodies pipe cleaner or pipe dream? 
  • Regulatory B cells as inhibitors of immune responses and inflammation. 
  • Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. 
  • Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients. 
  • Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. 
  • Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. 
  • Rituximab-associated progressive multifocal leukoencephalopathy after lung transplantation. 
  • Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. 
  • Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. 
  • Scavenging nucleic acid debris to combat autoimmunity and infectious disease. 
  • Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. 
  • Sex Differences in Treatment Strategies Among Patients With Ulcerative Colitis: A Retrospective Cohort Analysis of Privately Insured Patients. 
  • Short small-interfering RNAs produce interferon-α-mediated analgesia. 
  • Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. 
  • Specificity and sensitivity of glucocorticoid signaling in health and disease. 
  • Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response. 
  • Stromal gene signatures in large-B-cell lymphomas. 
  • Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Subcutaneous interferon alfa for the treatment of cutaneous pseudolymphoma. 
  • Successful management of refractory pediatric-onset complex aphthosis with lenalidomide. 
  • Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). 
  • Sweet host revenge: Galectins and GBPs join forces at broken membranes. 
  • Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). 
  • Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. 
  • The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options. 
  • The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 
  • The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide. 
  • The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series. 
  • The clinical relevance of alloantibody in liver transplantation. 
  • The genome of the sea urchin Stongylocentrotus purpuratus 
  • The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. 
  • The n-hexane and chloroform fractions of Piper betle L. trigger different arms of immune responses in BALB/c mice and exhibit antifilarial activity against human lymphatic filarid Brugia malayi. 
  • The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease. 
  • The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. 
  • Therapeutic advancements in juvenile idiopathic arthritis. 
  • Tocilizumab in Refractory Autoimmune Encephalitis: A Series of Pediatric Cases. 
  • Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates. 
  • Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS). 
  • Translational Research Working Group developmental pathway for immune response modifiers. 
  • Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. 
  • Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. 
  • Treatment of steroid-resistant nephrotic syndrome in the genomic era. 
  • Type III Hypersensitivity Reaction to Subcutaneous Insulin Preparations in a Type 1 Diabetic. 
  • Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency. 
  • Use of tumor necrosis factor inhibitors in uveitis. 
  • Vaccine therapy in non-small-cell lung cancer. 
  • Vincristine therapy for severe platelet alloimmunization. 
  • What's next for immunotherapy in locally advanced NSCLC? 
  • [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. 
• 

  Keywords of People

  • Allen, Nancy Bates, Professor Emeritus of Medicine, Medicine, Rheumatology and Immunology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Wray, Gregory Allan, Professor of Biology, Evolutionary Anthropology